Clinical trials: Nervous System Cancer
Brain Tumor, Central Nervous System Neoplasms
Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment
The aim of this study is to follow up with all of the pediatric brain tumor patients who received proton beam radiation therapy at Massachusetts General Hospital (MGH) for which there is baseline neuropsychological testing in…
- Trial name
- NCT01180881
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Massachusetts General Hospital
Posterior Fossa Lesion
Comparison of Surgical Outcomes of Craniotomy and Craniectomy in Posterior Fossa Lesions
The purpose of this randomized controlled trial is to compare the surgical outcomes of craniotomy and craniectomy among patients with posterior fossa lesions.
- Trial name
- NCT06831695
- Testing
- Craniotomy, Craniectomy
- Volunteers
- 80 people
- Sponsor
- University of Health Sciences Lahore
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Refractory Myasthenia Gravis, Rituximab
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
This study is designed to evaluate the effectiveness and safety of low-dose rituximab in patients with refractory myasthenia gravis.
- Trial name
- NCT05332587
- Testing
- Rituximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Neurofibromatosis Type 1, Reading Disabilities
Neurobiology and Treatment of Reading Disability in NF-1
The goal of this trial is to determine if children with neurofibromatosis type 1 who have reading disabilities respond the same way-both behaviorally and neurobiologically-to specialized treatment programs as children with…
- Trial name
- NCT00624234
- Testing
- Tutoring Program I, Tutoring Program II
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Brain Tumors, Central Nervous System Tumors
Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003935
- Testing
- etoposide, vincristine sulfate, radiation therapy
- Where
- 110 sites in United States, Australia and 4 more
- Volunteers
- 31 people
- Sponsor
- Children's Oncology Group
Cerebral Palsy (CP), Oncology
Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends
This is a prospective acceptability study to evaluate the gastrointestinal tolerance and compliance of a bolus tube feed over a 28 -day period for up to 50 participants.
- Trial name
- Blends (NCT07341464)
- Testing
- Tube feed
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Société des Produits Nestlé (SPN)
Neurofibromatosis 2, Vestibular Schwannoma
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor.
- Conditions
- Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma
- Trial name
- SEL-TH-1601 (NCT03095248)
- Testing
- Selumetinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Glial Tumor of Brain, Diffuse Intrinsic Pontine Glioma
Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
The primary aim of this study is to determine the presence of gemcitabine in childhood diffuse midline gliomas (DMG) (previously classified as diffuse intrinsic pontine glioma [DIPG]) after systemic treatment with the drug.
- Conditions
- Glial Tumor of Brain, Diffuse Intrinsic Pontine Glioma, Glioma
- Trial name
- NCT04051047
- Testing
- Gemcitabine, Tumor biopsy and blood draw
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Growth Hormone Deficiency, Neoplasms
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
The aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions.
- Conditions
- Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2
- Trial name
- NCT06709040
- Testing
- Somapacitan
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Brain Tumors, Solid Tumor
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Honest, clear, and empathetic communication between pediatric oncologists (POs) and parents of children with cancer (POCCs) is imperative to facilitating therapeutic alliance and ensuring that medical management aligns with the…
- Trial name
- NCT02846038
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor, Sarcoma
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who have locally…
- Trial name
- NCT00041249
- Testing
- brostallicin
- Where
- 16 sites in Belgium, France and 3 more
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain Tumors
Florida Center for Brain Tumor Research
The purpose of this research study is to collect and store brain tumor tissue samples for future research. The samples will become part of the University of Florida Brain Tumor Tissue Bank/Florida Center for Brain Tumor Research.
- Trial name
- FCBTR (NCT00811148)
- Testing
- Tissue Bank
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- University of Florida
Cardiac Disease, Cancer
Electronic Medical Records and Genomics (eMERGE) Phase III
The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clinically relevant, actionable genes.
- Conditions
- Cardiac Disease, Cancer, Hypercholesterolemia, Diabetes
- Trial name
- eMERGE (NCT03394859)
- Volunteers
- 25,380 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Tuberous Sclerosis
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
To assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the treatment of primary seizure types in patients with genetically- or clinically-confirmed TSC-related epilepsy through the end of the 12 week…
- Trial name
- TSC (NCT04285346)
- Testing
- Ganaxolone
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Marinus Pharmaceuticals
Stroke, Osteoporosis
Sarcopenia and Risk of Falls in Patients With Major Chronic Diseases
The objective of this study is to investigate the effects of therapeutic exercise and nutrition intervention for sarcopenia and risk of falls in patients with major chronic diseases.
- Conditions
- Stroke, Osteoporosis, Chronic Kidney Diseases, Cancer
- Trial name
- NCT03798418
- Testing
- elastic band strengthening exercise, diet counseling
- Where
- Taiwan
- Volunteers
- 186 people
- Sponsor
- Changhua Christian Hospital
Central Nervous System Tumor, Head and Neck Neoplasms
Expanded Access [11C] Methionine PET Imaging
The participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan…
- Trial name
- NCT05511714
- Testing
- L-(11C) methionine
- Where
- United States
- Sponsor
- St. Jude Children's Research Hospital
Sarcoma, Intracranial Neoplasm
Evaluation of Performance Characteristics and Applicability in Oncology of Devices Customized Medical Devices Made by 3D Printing
Technologies 3D are demonstrating enormous potential for innovation in the field of surgery,introducing the concept of "treatment customization" (from planning surgery to implant design and manufacturing) on the patient's…
- Conditions
- Sarcoma, Intracranial Neoplasm, Pelvic Bone Neoplasm
- Trial name
- NCT06291662
- Testing
- 3D printer applications
- Where
- 3 sites in Italy
- Volunteers
- 12 people
- Sponsor
- Kathleen McGreevy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.